Orally Ingestible Insulin Clinical Trial Recruitment Begins

Patient recruitment has begun in preparation for new clinical trials in Israel for the orally ingestible insulin capsule, ORMD-0801.

Oramed Pharmaceuitcals, a developer of oral drug delivery systems, is looking to trial the drug designed to treat patients with type 1 diabetes mellitus T1DM.

Past clinical studies show that administering the drug to T1DM patients before a meal was effective in keeping blood sugar levels stable, with results published in the peer-reviewed journal PLOS ONE.

Chief executive officer of Oramed, Nadav Kidron said: "We are very excited to continue our development of ORMD-08O1 for this high-need indication. We have been encouraged by our successful T1DM trials to date and we look forward to the commencement of this study."

There are many different ways to treat type 1 diabetes and this week Novo Nordisk announced that it had received FDA clearance for its pen device NovoPen Echo in the US.

The first device of its kind it uses half-unit dosing and a memory function, recording dosage and time between injections.